BIOMERICA, SLEEPING GIANT - 500 Beiträge pro Seite

[rdncoic]

Hmmm...Biomerica...oldmanbadman rdncoic

This is one stock worth watching and buying. It is a real sleeper, soon to rise to between 3 and 4 dollars U.S. oldmanbadman rdncoic

[rdncoic]

Antwort auf Beitrag Nr.: 30.741.323 von rdncoic am 18.07.07 11:03:19

Hmmm...DoYourOwnResearch...oldmanbadman rdncoic

Do your own research on this stock and do not take anyones else's word on it. Biomerica (BMRA) was a survivor of the last big stock market crash. It could not focus on the core business and got lost along the way. New management has taken over the company since the last 3 years and now they have produced 9 quarters of profit. Small profit, but profit still.

Lance Othidonics (LANZ) was attached to BMRA for a few years but now BMRA has cut off the association with LANZ, a good thing. They combined sales and profit with LANZ which caused the company to look bad. Now sales are up and profits are booming. MEDICUS (Not sure on the Spelling) in Stuttgart features Biomerica once a year for their home-test kits for medical problems.

5.9 million shares outstanding. Gar Nichts! You heard about BIOMERICA here, from the oldmanbadman rdncoic. This is your chance to make money and make it big. Look at the charts and you will see just what is going on here. No one is following this company on wall street. When they do start to look at it, watch out. oldmanbadman rdncoic

[rdncoic]

www.streetinvesting.com: Biomerica Inc. Receives Progressive Following

Jul 18, 2007 (M2 PRESSWIRE via COMTEX) -- Streetinvesting.com is the leading online financial newsletter community with thousands of investors from around the world. Our goal is to bring our theories and techniques to investors seeking a different and unique approach to investment ideas. We have a research team that has been built upon the premise of finding companies that we feel may interest investors looking for that unique and tactical edge.
Please visit www.Streetinvesting.com for the full report, additional research and related articles on the company mentioned herein.

Wall Street shed away the fear factor this Tuesday as the Dow Jones continues on its wild record breaking claims and blew the 14,000 cap for the very first time. Pulling the string behind the very bullish attitude which is currently plugging the whole market sentiment on Tuesday's session, the drivers are the mild inflation report assorted with an outburst of good earning reports and ever-going merger activities. Investors have lately been looking for guidance and this week positive economic readings and uninterrupted flow of acquisition news have shown them the light. However, the question that would slowly follow could be: How long would the good tidings last?' Most analysts dread that the extreme performance the Dow is showing could well be an illusion and not breed any factual substance. Biomerica Inc. (OTCBB: BMRA)

With the markets always running on a greed and fear factor, and investors always inclined to chase the mystery and anticipation principle, our research team has been surveying the facts and actualities that contribute to differentiate the prospective companies within the Over-The-Counter Bulletin Board. Biomerica Inc. was amongst those we have included in our pool of nominees and wish to bring to your attention.
On Tuesday July 17th, 2007, Biomerica Inc., a global provider of advanced diagnostic products for the early detection of medical conditions, made a press release, announcing that its board of directors has increased the size of the board from five to six members and elected John Roehm, President & CEO of Mollen Immunization Clinics of North America, to the board. From 1989 to 2006, Mr. Roehm served in a broad range of leadership positions with Albertsons / American Stores (Sav-on & Osco) including its Director of Pharmacy Marketing since 1999. He holds a B.S. degree in Pharmacy from Massachusetts College of Pharmacy.

"John's broad experience in chain drug pharmacy marketing and management will bring an enormous wealth of OTC and consumer knowledge to our Company," said Biomerica CEO and Chairman Zack Irani. "We are pleased that John has joined our Board as we increase our focus on the OTC drug store market."

"Biomerica is well positioned to take advantage of the growth in the consumer healthcare market," Mr. Roehm said. "I look forward to contributing to the Company as it grows."

The Company also recently elected Jane F. Emerson, M.D., Ph.D., Chief of Clinical Pathology and Vice-Chair for Clinical Affairs, Department of Pathology and Laboratory Medicine University of California, Irvine, to the board.

Biomerica Inc. (www.biomerica.com) is a global medical technology company, based in Newport Beach, CA. The Company manufactures and markets advanced diagnostic products used at home, in hospitals, and in physicians' offices for the early detection of medical conditions and diseases.
The rich flow of news still due for the week can either act as words of wisdom for the bulls or spell of doom for the bears. As investors' sentiment takes a boost on Tuesday's session, Streetinvesting.com will stay focused on our goal to provide future news and developments on Biomerica Inc., as we believe some interesting events or announcements will come forth. If you wish to be where the news about Biomerica Inc. would smell fresh and potent, simply visit www.streetinvesting.com and access our online information log about this company freely.

[rdncoic]

Hmmm...BiomericaNumbers...oldmanbadman rdncoic

Full year numbers will be out on BMRA on or about 30 August 2007. Plenty of time to do your DD (Due Diligence/research) on the stock. Plenty of bad people out there trying to get your money so watch out!

Just recently, BMRA received a cash injection of 697,000 U.S. Dollars (.12 cents a share from stock holdings which were cashed in) which will also help the bottom line. Profit on top of profit. Good for the business plan. Gives room to breath and expand.

I look for small companies that make money and are undervalued. Also dividend companies that are undervalued. I like to talk about what I find and can make no money from the discussion. You must make your own decisions and do not depend on me to tell you when to buy and when to sell. I do that on my own just like you do. Have a nice day. oldmanbadman rdncoic

[rdncoic]

Jul 17, 2007 08:19 ET
Biomerica Board of Directors Adds New Member
NEWPORT BEACH, CA--(Marketwire - July 17, 2007) - Biomerica, Inc. (OTCBB: BMRA), a global provider of advanced diagnostic products for the early detection of medical conditions, today announced that its board of directors has increased the size of the board from five to six members and elected John Roehm, President & CEO of Mollen Immunization Clinics of North America, to the board. From 1989 to 2006, Mr. Roehm served in a broad range of leadership positions with Albertsons / American Stores (Sav-on & Osco) including its Director of Pharmacy Marketing since 1999. He holds a B.S. degree in Pharmacy from Massachusetts College of Pharmacy.

"John's broad experience in chain drug pharmacy marketing and management will bring an enormous wealth of OTC and consumer knowledge to our Company," said Biomerica CEO and Chairman Zack Irani. "We are pleased that John has joined our Board as we increase our focus on the OTC drug store market."

"Biomerica is well positioned to take advantage of the growth in the consumer healthcare market," Mr. Roehm said. "I look forward to contributing to the Company as it grows."
The Company also recently elected Jane F. Emerson, M.D., Ph.D., Chief of Clinical Pathology and Vice-Chair for Clinical Affairs, Department of Pathology and Laboratory Medicine University of California, Irvine, to the board.

About Biomerica (OTCBB: BMRA)

Biomerica, Inc. (www.biomerica.com) is a global medical technology company, based in Newport Beach, CA. The Company manufactures and markets advanced diagnostic products used at home, in hospitals, and in physicians' offices for the early detection of medical conditions and diseases.

[rdncoic]

Biomerica Announces Income of $697,034 on Sale of Securities Held for Investment



Last Update: 8:20 AM ET Jun 20, 2007


NEWPORT BEACH, CA, Jun 20, 2007 (MARKET WIRE via COMTEX) -- Biomerica, Inc. (BMRA : Biomerica Inc
News , chart , profile , more
Last: 0.75+0.01+1.35%

8:13pm 07/23/2007

Delayed quote dataAdd to portfolio
Analyst
Create alertInsider
Discuss
Financials
Sponsored by:

BMRA0.75, +0.01, +1.4%) , a global provider of advanced diagnostic products for the early detection of medical conditions, announces income of $697,034 on the sale of the Hollister-Stier Laboratories securities it held for investment. The Hollister-Stier securities were held as an option to purchase shares in Hollister-Stier Laboratories LLC and were carried on Biomerica's balance sheet at a zero value as Hollister-Stier Laboratories is a private company. The acquisition of Hollister-Stier Laboratories by Jubilant Organosys Ltd. closed on June 1, 2007.
"The timing of this gain is fortuitous as we gear up to introduce new products and broaden our distribution in the up coming fiscal year," said Zackary Irani, Biomerica's Chief Executive Officer. Biomerica also holds 683,562 shares of common stock of Lancer Orthodontics, its formerly consolidated subsidiary.
Biomerica, Inc. ( www.biomerica.com) is a global medical technology company, based in Newport Beach, CA. The Company manufactures and markets advanced diagnostic products used at home, in hospitals, and in physicians' offices for the early detection of medical conditions and diseases.

[rdncoic]

Hmmm...BIOMERICA...oldmanbadman rdncoic

SO SO, Ich glaube es geht los. Ich wurde nur noch die nachtrichten posten.

Got Biomerica? Did you do your due diligence? How was that for a nice stock tip? In a down market, BIOMERICA is going up. I am not going to advise buy or sell, I am only going to make money like I always do.

The advice was for free. I didn't earn a Euro on giving free advice. Have a nice day all you Germans!

[rdncoic]

BIOMERICA INC. Registered Shares DL 0,08
31.07.07 09:22 Uhr
0,72 EUR

+22,03 % [+0,13]
KGVe:--

DIVe:
--
Typ: Aktie WKN: 866251

Börse: Berlin-Bremen

Börsenplatz wählenNASDAQ OTC BBBerlin-Bremen

[rdncoic]

Hmmm...GoingHigher...oldmanbadman rdncoic

31 August 2007 End of Year Results out. BEST YEAR EVER!oldmanbadman rdncoic

Cheap Shares will soon be all gone!

BIOMERICA INC. Registered Shares DL 0,08
01.08.07 09:44 Uhr

0,74 EUR
+2,78 % [+0,02]
KGVe:
--

DIVe:
--
Typ: Aktie WKN: 866251

Börse: Berlin-Bremen

Börsenplatz wählenNASDAQ OTC BBBerlin-Bremen

[rdncoic]

By: rdncoic2
04 Aug 2007, 05:32 AM EDT
Msg. 166 of 166
Jump to msg. #

Hmmm...MarkMyWords...oldmanbadman rdncoic

New End of Year Results on 31 Aug 2007 will be the best ever. Biomerica will be a solid buy for those interested in Personal Wealth Building. WOW! oldmanbadman rdncoic Look at those percentage gains in profit and cash on hand from May 2006 and May 2007. Gosh! Hot Damm, it looks like a huge chance for a buyout to me. The company has to look good to the big boys. Peanuts for the market players.

You heard it from the oldmanbadman. Got BMRA? Got Bucks!
Biomerica, Inc. (OTC:BMRA) Contact Information
Biomerica, Inc.
1533 Monrovia Ave.
Newport Beach, CA 92663
CA Tel. [phone]
Toll Free 800-854-3002
Fax [phone]
Type: Public
On the web: biomerica dot com
Employees: 27
Employee growth: (56.5%)

God bless Biomerica. The company makes diagnostic tests for use worldwide in hospitals, clinics, research laboratories, physicians' offices, and pharmacies, as well as testing kits that are sold over-the-counter. Biomerica's tests detect and monitor medical problems including allergies, cancer, infectious disease, diabetes, and other chronic diseases. Prior to 2006 Biomerica had a controlling interest in Lancer Orthodontics, which makes orthodontic products including arch wires, lingual attachments, and buccal tubes. The company lost its control of Lancer in 2005, however, and no longer counts the company's income as its own. Biomerica has manufacturing facilities in California and Mexico.

Key numbers for fiscal year ending May, 2006:
Sale: $7.2M
One year growth: (22.5%)
Net income: $0.2M
Income growth: 43.8%

Officers:
Chairman and CEO: Zackary S. Irani
CFO, Secretary, Treasurer, and Director: Janet Moore


Competitors:
Abbott Labs
Quidel
Siemens Medical Solutions Diagnostics




(Voluntary Disclosure: Position- Long; ST Rating- Strong Buy; LT Rating- Strong Buy)

[rdncoic]

Hmmm...Kaufangebot...oldmanbadman rdncoic

Very simple. I only invest in companies when management talks to me. I trade copanies (buy and sell) when management does not talk to me. I am very good in pushing my questions through to management because I do not waste their or my time with silly questions. I only bother management when I have a valid question or worry. I use email, the telephone, and I go on vacation each year and visit a different business that I own a large amount of shares in. (Only in companies that I have at least 1% to 5% of the issued shares)

So the answer to your question is "Talk to Management". Having said that, it is not easy building a relationship with management. But for example, it was easy to do this with Loop because of my wife's large amount of shares in Adultshop. (Over two Million and growing) Yes, I have talked to Paul and Martin about the business of Loop. And yes, I am investing in Loop and not trading Loop. Insider information? Of course not. Just investment questions and answers. All companies that are worth anything work on investor relations. (A little bit more witht the large investors)

Kaugangebot, it is called Due Dilligence! Study the company very closely before you put a lot of money into it.
I will give you an example of one of my investments that is getting ready to pop. BIOMERICA. I have a thread on this wallstreet address to access if you wish. I have been talking to management for years and I own about 3% of BMRA at present. Every year they come to Germany to present their products at the large medical messe. Every year, Me and my wife go to this messe and talk with management on the last day of the show. The last day is great because they are tearing down and have time to talk. A lot. My investment in BMRA is up over 100% as of last week. Good news is coming out on or about 31 Aug 07. Best End of Year Ever for BIOMERICA. I am looking at another 50 to 100% jump in value. Just watch it and you will see why I talk to management.

Sorry if you cannot understand English or understand what I do. My wife anc children are German also, and they don't understand a word I say! But that is another story. Good luck on your investing and have a nice day. oldmanbadman rdncoic

I look for small companies that make money and are undervalued. Also dividend companies that are undervalued. I like to talk about what I find and can make no money from the discussion. You must make your own decisions and do not depend on me to tell you when to buy and when to sell. I do that on my own just like you do. Have a nice day. oldmanbadman rdncoic

[rdncoic]

Biomerica Receives CE Mark Approval for 15-Minute Home Test for Ulcer Screening



Last Update: 8:19 AM ET Aug 7, 2007


NEWPORT BEACH, CA, Aug 07, 2007 (MARKET WIRE via COMTEX) -- Biomerica, Inc. (BMRA : Biomerica Inc
News , chart , profile , more
Last: 0.92-0.06-6.12%

7:41am 08/07/2007
BMRA0.92, -0.06, -6.1%) announced that it received CE mark approval for its 15-minute home diagnostic test for detecting Helicobacter pylori (H. pylori), a bacterium responsible for over 85% of ulcers. The one step test can now be marketed directly to consumers through drug stores in the European Union. Epidemiological studies have shown that the H. pylori infection is widespread, affecting over one billion people worldwide. It has been shown that nearly all duodenal ulcer patients and over 80% of stomach ulcer patients are infected with the bacterium. The disease affects both men and women. In addition to peptic ulcer disease, H. pylori infection has also been shown to be a significant risk factor for stomach cancer.
"This regulatory approval allows us to now sell our product to consumers throughout Europe," said Zackary Irani, CEO Biomerica. "We are already in discussions with several significant distributors." Biomerica's home test, which will be marketed under the trade name "FORTEL H.P. Ulcer Test," is a simple fifteen-minute test that individuals can perform in the privacy of their own home. The test utilizes an advanced technology that requires only a drop of a patient's blood.
It is estimated that the worldwide anti-ulcer market is over $9.5 billion. The FORTEL H.P. Ulcer Test is a part of BIOMERICA's line of easy to use tests designed to detect diseases before they become catastrophic, incurable or costly to treat.

[rdncoic]

Hmmm...Gosh...BMRA...isGETTINGreadyTOrockNroll...oldmanbadman rdnoic

Well I hope you all listened to me. It is not easy to make a buck on wall street. This is a big stock pick and you heard it from me. I am in already so I do not care when the SP POPS. News is coming near the end of August 07 and you can make some real money here.

What is it up today? 25%? (My real-time feed is down right now) 25% is peanuts. 5.9 million shares issued and only 7 million shares authorized. Even at 10+ bucks a share, that is giving BIOMERICA only a 60 to 70 million value. Hello. a buy out could/should be worth 100,000,000 for starters. oldmanbadman rdncoic

TRADERS, START YOUR ENGINES! WE ARE GETTING READY TO ROCK AND ROLL!

(Voluntary Disclosure: Position- Long; ST Rating- Strong Buy; LT Rating- Strong Buy)

[rdncoic]

Hmmm...UP25%TODAY...BIOMERICA...oldmanbadman rdncoic

Getting ready to pop! BMRA oldmanbadman rdncoic

[rdncoic]

Antwort auf Beitrag Nr.: 31.173.259 von rdncoic am 15.08.07 18:38:07

Insider Transactions by Biomerica Inc.

Past 90 Days The goals of BMRA.OB insiders are closely aligned with those of shareholders because insiders own a greater percentage of this company than at any other company in the Healthcare Equipment and Supplies industry. The 1,025,178 shares they control represents 19.44% of the total outstanding shares.

However, although insiders were net buyers of BMRA.OB shares during the last 3 months, they actually bought less than the average quarterly average for the last 2-years. While any insider buys are bullish, this signal is somewhat tempered in its strength.

(Why buy so many shares when you get options?) And they got them!

oldmanbadman rdncoic


(Voluntary Disclosure: Position- Long; ST Rating- Strong Buy; LT Rating- Strong Buy)

[rdncoic]

Antwort auf Beitrag Nr.: 31.210.521 von rdncoic am 17.08.07 20:23:20

Hmmm...BIOMERICA...oldmanbadman rdncoic


Company Description
Contact Info
1533 Monrovia Avenue

Newport Beach, CA 92663

United States

Phone: [phone]

Fax: [phone]

www.biomerica.com Biomerica, Inc. engages in the development, manufacture, and marketing of medical diagnostic products that are designed for the early detection and monitoring of chronic diseases and medical conditions. Its diagnostic test kits are used to analyze blood or urine from patients in the diagnosis of various diseases and other medical complications, or to measure the level of specific hormones, antibodies, antigens, or other substances, which might exist in the human body in small concentrations. The company’s clinical laboratory diagnostic products include tests primarily for thyroid conditions, food allergies, H. pylori, and diabetes. It offers its medical diagnostic products primarily to clinical laboratories, physicians’ offices, pharmaceutical companies, medical research institutions, and chain drugstores worldwide. The company was founded in 1971. It was formerly known as Nuclear Medical Systems, Inc. and changed its name to NMS Pharmaceuticals, Inc. in 1983, and then to Biomerica, Inc. in 1987. The company is headquartered in Newport Beach, California.

[rdncoic]

Antwort auf Beitrag Nr.: 31.214.264 von rdncoic am 18.08.07 11:13:27

BIOMERICA By: rdncoic2
28 Aug 2007, 01:27 PM EDT
Msg. 43831 of 43831
Jump to msg. #
Hmmm...RideUmCowboy...BMRA...oldmanbadman rdncoic

Make your money while you can. Oldmanbadman rdncoic gave you this one for free.

BIOMERICA INC - Nasdaq National Market: BMRA
1.43 0.26 (22.22) 13:04 1.31 (5) + 1.43 (5) 111,250
Latest Ticks Prev Close Open Low High Avg Day Vol
+=== 1.17 1.19 1.17 1.43 12,800
# of Trades Last Size Avg Trade Size 52 Wk Low 52 Wk High VWAP
85 750 1,309 0.38 1.15 1.2169
P/E Ratio Market Cap (mil) EPS Trailing Div Yield Beta UPC
20 8 0.07 0.0 0.52 N


(Voluntary Disclosure: Position- Long; ST Rating- Strong Buy; LT Rating- Strong Buy)

[rdncoic]

Antwort auf Beitrag Nr.: 31.214.264 von rdncoic am 18.08.07 11:13:27

BIOMERICA By: rdncoic2
28 Aug 2007, 01:27 PM EDT
Msg. 43831 of 43831
Jump to msg. #
Hmmm...RideUmCowboy...BMRA...oldmanbadman rdncoic

Make your money while you can. Oldmanbadman rdncoic gave you this one for free.

BIOMERICA INC - Nasdaq National Market: BMRA
1.43 0.26 (22.22) 13:04 1.31 (5) + 1.43 (5) 111,250
Latest Ticks Prev Close Open Low High Avg Day Vol
+=== 1.17 1.19 1.17 1.43 12,800
# of Trades Last Size Avg Trade Size 52 Wk Low 52 Wk High VWAP
85 750 1,309 0.38 1.15 1.2169
P/E Ratio Market Cap (mil) EPS Trailing Div Yield Beta UPC
20 8 0.07 0.0 0.52 N


(Voluntary Disclosure: Position- Long; ST Rating- Strong Buy; LT Rating- Strong Buy)

[rdncoic]

Antwort auf Beitrag Nr.: 31.320.279 von rdncoic am 28.08.07 19:34:57

BIOMERICA 52 WEEK HIGH! 1.40 U.S. Dollars. HOT HOT HOT

[rdncoic]

Antwort auf Beitrag Nr.: 31.324.407 von rdncoic am 29.08.07 09:13:06

Hmmm...PSST...PSST...PSST...oldmanbadman rdncoic

Numbers due tomorrow! 30 August 2007. Got BMRA? Then you got BIG BUCKS! Oh well, if you don't have BMRA, it was only money. And no one needs money???? oldmanbadman rdncoic

(Voluntary Disclosure: Position- Long; ST Rating- Strong Buy; LT Rating- Strong Buy)

[rdncoic]

Antwort auf Beitrag Nr.: 31.325.555 von rdncoic am 29.08.07 10:33:19

BIOMERICA Consolidated net income was $536,879 for the year ended May 31, 2007. Prior to recording the expense ($100,000) for employee bonuses according to the Management Incentive Plan, consolidated net income was $636,879. Stand-alone income from diagnostic operations before interest in net loss or income of consolidated subsidiaries and income taxes was $525,779 for fiscal 2007 as compared to $222,041 for fiscal 2006.

This represents an increase of $303,738, or 136.8%.

The increase was primarily due to increased sales.

[rdncoic]

Antwort auf Beitrag Nr.: 31.338.034 von rdncoic am 30.08.07 09:33:43

Biomerica Announces Record Year End Results
Diagnostic Sales up Over 34%; Diagnostic Income up Over 133%
Last Update: 8:20 AM ET Aug 30, 2007Print E-mail Subscribe to RSS Disable Live Quotes NEWPORT BEACH, CA, Aug 30, 2007 (MARKET WIRE via COMTEX) -- Biomerica, Inc. (BMRA:Biomerica Inc

BMRA 1.30, -0.10, -7.1%) , a global provider of advanced diagnostic products for the early detection of medical conditions, today reported stand-alone results of diagnostic net sales of $5,748,319 for the fiscal year 2007 ended May 31, 2007, compared to stand-alone results of diagnostic net sales of $4,259,954 in fiscal 2006, an increase of $1,488,365 or 34.9%.
Biomerica announced consolidated net income (including stock option expenses) for the fiscal year 2007 ended May 31, 2007, of $536,879, versus consolidated net income of $230,273 in fiscal 2006, an increase of 133.1%. Consolidated basic earnings per common share were $.09 for fiscal 2007 as compared to $.04 for fiscal 2006. Consolidated basic earnings per common share for continuing operations were $.09 for fiscal 2007 as compared to $.03 for fiscal 2006. Prior to recording the expense of $100,000 for employee bonuses according to the Biomerica Incentive Plan, consolidated net income was $636,879. Prior to recording employee stock option expenses of $123,584 and the above incentive plan, consolidated net income was $760,463.
Stand-alone income from diagnostic operations before interest in net loss or income of consolidated subsidiaries and income taxes was $525,779 in fiscal 2007 as compared to $222,041 in fiscal 2006. This represents an increase of $303,738, or 136.8%.
"We are pleased with the continuing progress in our financial performance in both sales and especially income," stated Zackary Irani, Biomerica CEO. "This was the first year that the Company adopted the expensing of employee stock options (SFAS #123R) yet we were still able to achieve financial results above our plan. As we expand our marketing efforts to increase distribution and move forward with planned new product introductions, we expect that fiscal 2008 will continue to show improvements in our performance."
About Biomerica (BMRA:Biomerica Inc
News, chart, profile, more
Last: 1.30-0.10-7.14%

3:46pm 08/29/2007

[rdncoic]

Antwort auf Beitrag Nr.: 31.342.368 von rdncoic am 30.08.07 14:51:01

Hmmm...EasyMoney101...oldmanbadman rdncoic

Well that was easy money 101 if anyone was reading my posts and bought BMRA. Too Easy. But not to worry, BMRA is going to slide sideways for a while and good chances to buy will be there again before the next good news creats another pop. Hope some of you Germans were able to make some money.

Oldmanbadman rdncoic

Remember, U B Bad or U B Sad!

[rdncoic]

Antwort auf Beitrag Nr.: 31.364.646 von rdncoic am 01.09.07 16:13:25

Hmmm...HatKeinEinzigenDeutscher...oldmanbadman rdncoic

Bloss ein Frage. Hat Kein Einzigen Deutscher heir profitiert von meinen BIOMERICA pick? Unbelievable! Ich bin uber 100,000 U.S. Dollar im Plus im moment. Ich wollte nur euch helfen zum reichtum. Und Warum.....?

Weil, nachdem Sie alle Angie Merkel gewahlt habem, haben Sie ihren suppe bekommen. UND JETZT? Jetzt haben sie alle die Merkel Steuer auf den buckel. Wahnsinn. 33 % steuer von sie den Lohn bekomme, und dann 19% steuer wann Sie es aus gibt.

Aber wir wissen alle: Ein Deutscher kennt Keinen Schmerz!

What ever happened to the good Germans? Did they die out or did they all go to Amerika? Sad. Nothing left here but a bunch of silly Socialists and communist Lefties. Germany fought two World Wars for World Domination, Killed millions of innocent people, and now no one in Germany would even fight to free one single person.

The Muslims are going to take over Germany and Europe, turn the churches into Muslim churches, put all the women into burkas, and have lots of children who will grow up and kill all you non-believers. Shame. You are all willing to march for peace, but not one of you are willing to die for freedom. America freed you from the communists, and most of you thank god for Gorbachov, WHAT ABOUT RONALD REAGAN? He saved Europe for you all.

Oh well, Have a nice day and don't worry about my rants. I am just an old U.S. Infantry Soldier in retirement here in Germany. (Yes YOU CALLED US BABY KILLERS) Go ahead and insult me if you wish. Make money on me if you dare. And most of all, say something bad about America today. Old Gerhart Sooodahah (Schroder) talked his way into two terms in Germany by attacking America day and night. With his french buddy Jackass Chirac. Soon Iran will have the A-Bomb and Europe will surrender without a fight. And ole Gerhard Sooodahah is laughing all the way to his Russian Bank Account.laugh: oldmanbadman rdncoic

[rdncoic]

Antwort auf Beitrag Nr.: 30.741.323 von rdncoic am 18.07.07 11:03:19

Stock To Watch - BMRA (Biomerica, Inc.)

Biomerica Receives CE Mark Approval for 15-Minute Home Test for Ulcer Screening
TUESDAY, AUGUST 07, 2007 8:19 AM - Market Wire

NEWPORT BEACH, CA, Aug 07, 2007 (MARKET WIRE via COMTEX) -- Biomerica, Inc. (BMRA) announced that it received CE mark approval for its 15-minute home diagnostic test for detecting Helicobacter pylori (H. pylori), a bacterium responsible for over 85% of ulcers. The one step test can now be marketed directly to consumers through drug stores in the European Union.
Epidemiological studies have shown that the H. pylori infection is widespread, affecting over one billion people worldwide. It has been shown that nearly all duodenal ulcer patients and over 80% of stomach ulcer patients are infected with the bacterium. The disease affects both men and women. In addition to peptic ulcer disease, H. pylori infection has also been shown to be a significant risk factor for stomach cancer.
"This regulatory approval allows us to now sell our product to consumers throughout Europe," said Zackary Irani, CEO Biomerica. "We are already in discussions with several significant distributors."
Biomerica's home test, which will be marketed under the trade name "FORTEL H.P. Ulcer Test," is a simple fifteen-minute test that individuals can perform in the privacy of their own home. The test utilizes an advanced technology that requires only a drop of a patient's blood.
It is estimated that the worldwide anti-ulcer market is over $9.5 billion. The FORTEL H.P. Ulcer Test is a part of BIOMERICA's line of easy to use tests designed to detect diseases before they become catastrophic, incurable or costly to treat.
About Biomerica (BMRA)
Biomerica, Inc. (www DOT biomerica.com) is a global medical technology company, based in Newport Beach, CA. The Company manufactures and markets advanced diagnostic products used at home, in hospitals, and in physicians' offices for the early detection of medical conditions and diseases.
The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements. Certain information included in this press release (as well as information included in oral statements or other written statements made or to be made by Biomerica) contains statements that are forward-looking; such as statements relating to intended launch dates, sales potential, significant benefits, market size, growth of business, favorable positions, expansion, expected orders, leading market positions, anticipated future revenues or production volume of the Company, success of product and new product offerings. Such forward-looking information involves important risks and uncertainties that could significantly affect anticipated results in the future, and accordingly, such results may differ materially from those expressed in any forward-looking statements made by or on behalf of Biomerica. The potential risks and uncertainties include, among others, fluctuations in the Company's operating results due to its business model and expansion plans, downturns in international and or national economies, the Company's ability to raise additional capital, the competitive environment in which the Company will be competing, and the Company's dependence on strategic relationships. The Company is under no obligation to update any forward-looking statements after the date of this release.

[rdncoic]

Antwort auf Beitrag Nr.: 30.741.323 von rdncoic am 18.07.07 11:03:19

Medical Testing Company **BIOMERICA** Expanding, Targets Niche

By Jessica C. Lee


Biomerica Inc. is putting health to the test.

The Newport Beach-based company generates about $6 million in yearly sales making and selling diagnostic tests for hospitals, doctors and consumers. It is expanding its product lines trying to carve a niche in the competitive field.

Biomerica’s tests detect a wide range of health concerns such as allergies, diabetes, colon disease, pregnancy and drug usage.

The company’s tests are sold under the EZ Detect and Fortel brands. A good chunk of Biomerica’s business is making diagnostic tests for other companies that then package and sell them as their own.

Biomerica sells its tests through retailers such as Deerfield, Ill.-based Walgreen Co., CVS Corp. of Rhode Island and Pennsylvania’s Rite-Aid Corp. It taps distributors to sell tests to hospitals and clinics such as Newport Beach’s Hoag Memorial Hospital Presbyterian, Huntington Beach Hospital and clinics owned by Mayo Foundation for Medical Education and Research of Rochester, Minn.

Inside Biomerica’s 25,000-square-foot headquarters, the company’s 30 or so workers develop the key components for its tests. The products are assembled and packaged at Biomerica’s 10,000-square-foot factory in Mexicali, Mexico, where it employs about 20 people.

Biomerica stores its tests in Newport Beach and Mexico and uses outside carriers to ship them.

Competition in the diagnostic test business is tough, according to Zackary Irani, Biomerica’s chief executive.

A handful of companies make tests for the medical industry including heavyweights such as Fullerton’s Beckman Coulter Inc. and Abbot Laboratories of Abbot Park, Ill. Biomerica tries to avoid getting slammed by competitors with specialized products such as its food allergy tests and its over-the-counter colon disease tests, Irani said.

Diagnostic tests: Biomerica Inc. expanding product lines


“There’s a lot of competition out there, which makes it hard for a smaller company like us. We’re trying to stand out by carving a niche,” Irani said.

Irani’s uncle Joseph Irani and partner Ishkan Sultanian started Biomerica, then Nuclear Medical Systems Inc., in 1971. It changed its name to NMS Pharmaceuticals Inc. in 1983, about the same time Joseph Irani and Sultanian took the company public and started trading shares on the low profile, over the counter Bulletin Board exchange. The company became Biomerica in 1987.

Like most small businesses, Biomerica had to overcome the challenges of limited money and help. The company also has had to shift its focus by narrowing its product line, Zackary Irani said.

“We had too many products when we started. Over the years we’ve really narrowed our focus down and that’s helped us grow,” Irani said.

Zackary Irani first worked in the company’s accounting department and later climbed his way up in the business, he said. After his uncle died about seven years ago, Irani became interim chief executive—a position that later was made permanent.

While Irani worked his way up in the company, he said finding the right workers that will invest that kind of time is a challenge for the company. So far, Biomerica’s been fortunate to find some recruits from UC Irvine.

“It’s always a challenge to find workers and we’re actively looking for scientists,” he said.

While adding scientists will help the company grow, Biomerica also is staying on top of health concerns, Irani said, to push its expansion. The growing awareness of cancerous diseases, allergies, diabetes and other issues are helping Biomerica reach out to consumers seeking the benefits of early detection tests, he said.

To capture new business, Biomerica is creating more products for the over-the-counter consumer market and clinical market, Irani said. Tests that detect bone and mineral loss, allergies and diabetes are in the works.

Biomerica is also planning to move its headquarters, Irani said. The company has outrgrown its Newport Beach location and is looking for a larger building in a nearby, yet more affordable, OC city such as Irvine or Huntington Beach, he said.

“We’re trying to find the right space for us to grow into,” Irani said.

[rdncoic]

Antwort auf Beitrag Nr.: 30.741.323 von rdncoic am 18.07.07 11:03:19

Hmmm...VeryNiceUpwardMovementBMRA...oldmanbadman rdncoic

Last SP was 1.76 U.S. Dollar a share*********


By BMRA it is another story about success. Very nice upward movement and accumulation being done and only sales from profit taking shareholders. Slow and deliberate gain in SP. This is one to hold and be happy that it is in your depot. (Portfolio) I like it. I got it. And I am keeping it. Got BMRA? Then you got Big Bucks! oldmanbadman rdncoic

P.S. Please do not place all your eggs in one basket. Please remember that I am a very accomplished trader of stock. I get in early and I mostly get out with full profit while the first lemmings are backing up the truck. I am a big boy and I am not afraid to take risk. Or take profit!

(Voluntary Disclosure: Position- Long; ST Rating- Strong Buy; LT Rating- Strong Buy)

[rdncoic]

Antwort auf Beitrag Nr.: 30.741.323 von rdncoic am 18.07.07 11:03:19

Hmmm...BIOMERICA***Uber100%***...oldmanbadman rdncoic

Uber 100% zeit 18.07.19 Nicht Schlecht sagt der anleger!

HA HA HA Don't you wish you had BIOMERICA! Losers. oldmanbadman rdncoic

Der oldmanbadman rdncoic kennt aktien. Und wie mann Geld machen kann damit!

[rdncoic]

Antwort auf Beitrag Nr.: 31.833.656 von rdncoic am 03.10.07 18:47:42

Hmmm. ..BIOMERICA***Uber100%***.. .oldmanbadman rdncoic

Jeden Tag gibts mehr gewinn! Mehr und Mehr. Uber 110% zeit 18.07.19 Nicht Schlecht sagt der Specht!

HA HA HA :laughon't you wish you had BIOMERICA! Losers. oldmanbadman rdncoic

Der oldmanbadman rdncoic kennt aktien. Und wie mann Geld machen kann damit!

[rdncoic]

Antwort auf Beitrag Nr.: 31.837.459 von rdncoic am 04.10.07 08:52:07

Income From Operations Up Over 385%; First Quarter Basic EPS $0.15; Diagnostic Sales Up Over 16%
Biomerica Announces First Quarter Financial Results


Last Update: 7:47 AM ET Oct 16, 2007Print E-mail Subscribe to RSS Disable Live Quotes

NEWPORT BEACH, CA, Oct 16, 2007 (MARKET WIRE via COMTEX) -- Biomerica, Inc. (BMRA:Biomerica Inc
News, chart, profile, more
Last: 1.80+0.04+2.27%

9:32am 10/16/2007

Delayed quote dataAdd to portfolio
Analyst
Create alertInsider
Discuss
Financials
Sponsored by:
BMRA 1.80, +0.04, +2.3%) , a global provider of advanced diagnostic products for the early detection of medical conditions, today reported diagnostic net sales of $1,340,065 for the first quarter fiscal 2008 ended August 31, 2007, compared to diagnostic net sales of $1,153,266 in the first fiscal quarter 2007, an increase of 16.2%.
Biomerica announced consolidated net income (including stock option expenses) for the first quarter fiscal 2008 ended August 31, 2007 of $885,386, versus consolidated net income of $36,703 in fiscal 2007. Consolidated basic earnings per common share were $0.15 for the first quarter of fiscal 2008 as compared to $.01 for fiscal 2007. This includes income of $697,034 on the sale of the Hollister-Stier Laboratories securities Biomerica held for investment.
Consolidated operating income (not including the gain on the sale of Hollister-Stier securities) for the first quarter fiscal 2008 ended August 31, 2007 was $214,417 (or $0.04 Basic EPS), versus consolidated operating income of $44,195 ($0.01 Basic EPS) in fiscal 2007, an increase of over 385%.
"We delivered another strong quarter in earnings as we work to execute our yearly plan across all aspects of our diagnostic business," stated Zackary Irani, Biomerica CEO. "As we achieve milestones in expected new product introductions, we believe that fiscal 2008 will show improvements in our performance especially in the last two quarters of the fiscal year."


(Voluntary Disclosure: Position- Long; ST Rating- Strong Buy; LT Rating- Strong Buy)